InvestorsHub Logo
Followers 14
Posts 514
Boards Moderated 0
Alias Born 09/09/2017

Re: None

Friday, 02/11/2022 10:58:55 PM

Friday, February 11, 2022 10:58:55 PM

Post# of 232496
Re: this mAb called bebtelovimab (EUA authorized today to treat mild to moderate cases of the coronavirus), does anyone know how their study results compare with out NEWS2 results from 18 months ago? Wasn't NEWS2 also a mild-to-moderate COVID cohort?

I got the following off the YMB for side effects:

"Possible side effects of bebtelovimab include itching, rash, infusion-related reactions, nausea and vomiting. Serious and unexpected adverse events including hypersensitivity, anaphylaxis and infusion-related reactions have been observed with other SARS-CoV2 monoclonal antibodies and could occur with bebtelovimab."

Would it be fair to say our mAb is at least as good as Eli Lily's mAB, but Leronlimab is a much safer drug?

Does bebtelovimab have ANY advantage over Leronlimab?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News